Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III trial of Pimavanserin as an adjunctive treatment for Major Depressive Disorder

Trial Profile

A Phase III trial of Pimavanserin as an adjunctive treatment for Major Depressive Disorder

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use

Most Recent Events

  • 04 Dec 2018 New trial record
  • 31 Oct 2018 According to an Acadia Pharmaceuticals media release, the company is looking forward to meet with the FDA and initiate this trial in the first half of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top